<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GLYCOPYRROLATE</span><br/>(glye-koe-pye'roe-late)<br/><span class="topboxtradename">Robinul, </span><span class="topboxtradename">Robinul Forte<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antimuscarinic</span>; <span class="classification">antispasmodic</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg tablets; 0.2 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic anticholinergic (antimuscarinic) compound with pharmacologic effects similar to those of atropine. Inhibits muscarinic
         action of acetylcholine or autonomic neuroeffector sites innervated by postganglionic cholinergic nerves.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits motility of GI tract and genitourinary tract and decreases volume of gastric and pancreatic secretions, saliva, and
         perspiration.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive management of peptic ulcer and other GI disorders associated with hyperacidity, hypermotility, and spasm. Also
         used parenterally as preanesthetic and intraoperative medication and to reverse neuromuscular blockade.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Glaucoma; asthma; prostatic hypertrophy, obstructive uropathy; obstructive lesions or atony of GI tract; severe ulcerative
         colitis; myasthenia gravis; tachycardia; during cyclopropane anesthesia; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Autonomic neuropathy, hepatic or renal disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Peptic Ulcer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg t.i.d or 2 mg b.i.d. or t.i.d. in equally divided intervals (max: 8 mg/d), then decrease to 1 mg b.i.d. <span class="rdroute">IM/IV</span> 0.10.2 mg as single dose t.i.d. or q.i.d.<br/><br/><span class="indicationtitle">Reversal of Neuromuscular Blockade</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.2 mg glycopyrrolate administered with 1 mg of neostigmine or 5 mg pyridostigmine<br/><br/><span class="indicationtitle">Control of Secretions</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 40100 mcg/kg t.i.d.q.i.d. <span class="rdroute">IM/IV</span> 410 mcg/kg t.i.d.q.i.d.<br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 12 mg/dose b.i.d. or t.i.d. <span class="rdroute">IM/IV</span> 0.10.2 mg/dose given q48h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to meals.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give undiluted, deep into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  Inspect for cloudiness and discoloration. Discard if present. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 0.2 mg or fraction thereof over 12 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Methylprednisolone,</b> <b>chloramphenicol,</b> <b>dexamethasone,</b> <b>diazepam,</b> <b>dimenhydrinate,</b> <b>methohexital,</b> <b>pentazocine,</b> <b>phenobarbital,</b> <b>secobarbital,</b> <b>sodium bicarbonate,</b> <b>thiopental.</b> <span class="incompattype">Y-site:</span> <b>Diazepam,</b> <b>dimenhydrinate,</b> <b>methohexital,</b> <b>pentazocine,</b> <b>phenobarbital,</b> <b>secobarbital,</b> <b>thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Decreased sweating,</span> weakness. <span class="typehead">CNS:</span> Dizziness, drowsiness, overdosage (<span class="speceff-life">neuromuscular blockade</span> with curare-like action leading to muscle weakness and <span class="speceff-life">paralysis</span> is possible). <span class="typehead">CV:</span> Palpitation, tachycardia. <span class="typehead">GI:</span> <span class="speceff-common">Xerostomia,</span> constipation. <span class="typehead">GU:</span> <span class="speceff-common">Urinary hesitancy or retention</span>. <span class="typehead">Special Senses:</span> Blurred vision, mydriasis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <b>Amantadine,</b> <span class="classification">antihistamines</span>, <span class="classification">tricyclic antidepressants</span>, <b>quinidine,</b> <b>disopyramide,</b> <b>procainamide</b> compound anticholinergic effects; decreases <b>levodopa</b> effects; <b>methotrimeptrazine</b> may precipitate extrapyramidal effects; decreases antipsychotic effects (decreased absorption) of <span class="classification">phenothiazines</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly and incompletely absorbed from GI tract. <span class="typehead">Onset:</span> 1 min IV; 1530 min IM/SC; 1 h PO. <span class="typehead">Peak:</span> 3045 min IM/SC; 1 h PO. <span class="typehead">Duration:</span> 27 h IM/SC; 812 h PO. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead"> Metabolism:</span> Minimally metabolized in liver. <span class="typehead">Elimination:</span> 85% excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Incidence and severity of adverse effects are generally dose related.</li>
<li>Monitor I&amp;O ratio and pattern particularly in older adults. Watch for urinary hesitancy and retention.</li>
<li>Monitor vital signs, especially when drug is given parenterally. Report any changes in heart rate or rhythm.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid high environmental temperatures (heat prostration can occur because of decreased sweating).</li>
<li>Do not drive or engage in other potentially hazardous activities requiring mental alertness until response to drug is known.</li>
<li>Use good oral hygiene, rinse mouth with water frequently and use a saliva substitute to lessen effects of dry mouth.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>